Clinical Trial Update: Subcutaneous Administration of Otelixizumab to T1DM Patients [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating subcutaneous otelixizumab in patients with type 1 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Otelixizumab (otelixizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 1 | Phase 1 | Status: COMPLETED